TY - JOUR
T1 - The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms
AU - Kabata, Hiroki
AU - Moro, Kazuyo
AU - Koyasu, Shigeo
N1 - Funding Information:
MSD Life Science Foundation; Grant-in-Aid for Scientific Research (B), Grant/Award Number: 26293110; Grant-in-Aid for Challenging Exploratory Research, Grant/ Award Number: 24659373; Grant-in-Aid for Scientific Research on Innovative Areas, Grant/Award Number: 15H01166; Practical Research Project for Allergic Diseases and Immunology, Grant/Award Number: 16764150; The Nakajima Foundation; The Uehara Memorial Foundation; The Mochida Memorial Foundation for Medical and Pharmaceutical Research; Grant-in-Aid for Scientific Research (S), Grant/Award Number: 22229004; Grant-in-Aid for Scientific Research (A), Grant/Award Number: 16H02631
Funding Information:
We thank Anne-Laure Flamar for critical reading of the manuscript. H. K. was supported by Overseas Research Fellowships from the Japan Society for the Promotion of Science (JSPS) and MSD Life Science Foundation. K. M. was supported by a Grant-in-Aid for Scientific Research (B) (26293110) and a Grant-in-Aid for Challenging Exploratory Research (24659373) from JSPS, a Grant-in-Aid for Scientific Research on Innovative Areas (15H01166) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, a Practical Research Project for Allergic Diseases and Immunology (16764150) from the Japan Agency for Medical Research and Development (AMED), and grants from The Nakajima Foundation, The Uehara Memorial Foundation, and The Mochida Memorial Foundation for Medical and Pharmaceutical Research. S. K. was supported by a Grant-in-Aid for Scientific Research (S) (22229004), a Grant-in-Aid for Scientific Research (A) (16H02631), and a Grant-in-Aid for Challenging Exploratory Research (25670235) from JSPS.
Publisher Copyright:
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2018/11
Y1 - 2018/11
N2 - Group 2 innate lymphoid cells (ILC2s) play critical roles in the induction of type 2 inflammation, response to parasite infection, metabolic homeostasis, and tissue repair. These multifunctional roles of ILC2s are tightly controlled by complex regulatory systems in the local microenvironment, the disruption of which may cause various health problems. This review summarizes up-to-date knowledge regarding positive and negative regulators for ILC2s based on their function and signaling pathways, including activating cytokines (IL-33, IL-25; MAPK, NF-κB pathways), co-stimulatory cytokines (IL-2, IL-7, IL-9, TSLP; STAT5, IL-4; STAT6, TNF superfamily; MAPK, NF-κB pathways), suppressive cytokines (type1 IFNs, IFN-γ, IL-27; STAT1, IL-10, TGF-β), transdifferentiation cytokines (IL-12; STAT4, IL-1β, IL-18), lipid mediators (LTC4, LTD4, LTE4, PGD2; Ca2+-NFAT pathways, PGE2, PGI2; AC/cAMP/PKA pathways, LXA4, LTB4), neuropeptides (NMU; Ca2+-NFAT, MAPK pathways, VIP, CGRP, catecholamine, acetylcholine), sex hormones (androgen, estrogen), nutrients (butyrate; HDAC inhibitors, vitamins), and cell-to-cell interactions (ICOSL-ICOS; STAT5, B7-H6-NKp30, E-cadherin-KLRG1). This comprehensive review affords a better understanding of the regulatory network system for ILC2s, providing impetus to develop new treatment strategies for ILC2-related health problems.
AB - Group 2 innate lymphoid cells (ILC2s) play critical roles in the induction of type 2 inflammation, response to parasite infection, metabolic homeostasis, and tissue repair. These multifunctional roles of ILC2s are tightly controlled by complex regulatory systems in the local microenvironment, the disruption of which may cause various health problems. This review summarizes up-to-date knowledge regarding positive and negative regulators for ILC2s based on their function and signaling pathways, including activating cytokines (IL-33, IL-25; MAPK, NF-κB pathways), co-stimulatory cytokines (IL-2, IL-7, IL-9, TSLP; STAT5, IL-4; STAT6, TNF superfamily; MAPK, NF-κB pathways), suppressive cytokines (type1 IFNs, IFN-γ, IL-27; STAT1, IL-10, TGF-β), transdifferentiation cytokines (IL-12; STAT4, IL-1β, IL-18), lipid mediators (LTC4, LTD4, LTE4, PGD2; Ca2+-NFAT pathways, PGE2, PGI2; AC/cAMP/PKA pathways, LXA4, LTB4), neuropeptides (NMU; Ca2+-NFAT, MAPK pathways, VIP, CGRP, catecholamine, acetylcholine), sex hormones (androgen, estrogen), nutrients (butyrate; HDAC inhibitors, vitamins), and cell-to-cell interactions (ICOSL-ICOS; STAT5, B7-H6-NKp30, E-cadherin-KLRG1). This comprehensive review affords a better understanding of the regulatory network system for ILC2s, providing impetus to develop new treatment strategies for ILC2-related health problems.
KW - IL-25
KW - IL-33
KW - ILC2
KW - TSLP
UR - http://www.scopus.com/inward/record.url?scp=85054366470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054366470&partnerID=8YFLogxK
U2 - 10.1111/imr.12706
DO - 10.1111/imr.12706
M3 - Review article
C2 - 30294963
AN - SCOPUS:85054366470
SN - 0105-2896
VL - 286
SP - 37
EP - 52
JO - Immunological Reviews
JF - Immunological Reviews
IS - 1
ER -